Treatment of low high-density lipoprotein cholesterol

Zuhier Awan, Khalid Al Waili, Khalid Alrasadi, Jacques Genest

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The prevention of atherosclerotic vascular disease has changed considerably with the recognition that modifying cardiovascular risk factors (smoking, obesity, physical inactivity, elevated blood pressure, poor dietary habits, diabetes and elevated cholesterol levels) leads to a marked reduction in cardiovascular events. Reducing low-density lipoprotein cholesterol in high-risk subjects reduces cardiac events, cardiovascular mortality and total mortality. While epidemiological studies have consistently shown an inverse relationship between a low high-density lipoprotein cholesterol (HDL-C) level and the risk of coronary artery disease (CAD), there is a paucity of data showing unambiguously that raising HDL-C by pharmacological means reduces cardiac events. Lifestyle changes associated with an increase in HDL-C (smoking cessation, weight reduction, exercise, moderate alcohol intake) stand on their own merits with respect to cardiovascular benefits. Currently, the only available medication to raise HDL-C is nicotinic acid (niacin), taken in gram quantities. The data supporting niacin use for CAD prevention are much weaker than that for statins. Novel therapies aimed at raising HDL-C are the direct result of research in the complex mechanisms that modulate HDL in humans. These novel therapies will need to be tested not only for their ability to effectively and safely raise HDL-C, but for their ability to prevent CAD as well.

Original languageEnglish
JournalCanadian Journal of Cardiology
Volume24
Issue numberSUPPL.C
DOIs
Publication statusPublished - Aug 2008

Fingerprint

LDL Cholesterol
HDL Cholesterol
Niacin
Coronary Artery Disease
Aptitude
Dietary Cholesterol
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Mortality
Feeding Behavior
Smoking Cessation
Hypercholesterolemia
Vascular Diseases
Life Style
Weight Loss
Epidemiologic Studies
Obesity
Smoking
Alcohols
Pharmacology
Blood Pressure

Keywords

  • Dyslipidemia
  • HDL-cholesterol
  • Prevention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Treatment of low high-density lipoprotein cholesterol. / Awan, Zuhier; Waili, Khalid Al; Alrasadi, Khalid; Genest, Jacques.

In: Canadian Journal of Cardiology, Vol. 24, No. SUPPL.C, 08.2008.

Research output: Contribution to journalArticle

@article{1a343f669d2948a392ad531f070f2212,
title = "Treatment of low high-density lipoprotein cholesterol",
abstract = "The prevention of atherosclerotic vascular disease has changed considerably with the recognition that modifying cardiovascular risk factors (smoking, obesity, physical inactivity, elevated blood pressure, poor dietary habits, diabetes and elevated cholesterol levels) leads to a marked reduction in cardiovascular events. Reducing low-density lipoprotein cholesterol in high-risk subjects reduces cardiac events, cardiovascular mortality and total mortality. While epidemiological studies have consistently shown an inverse relationship between a low high-density lipoprotein cholesterol (HDL-C) level and the risk of coronary artery disease (CAD), there is a paucity of data showing unambiguously that raising HDL-C by pharmacological means reduces cardiac events. Lifestyle changes associated with an increase in HDL-C (smoking cessation, weight reduction, exercise, moderate alcohol intake) stand on their own merits with respect to cardiovascular benefits. Currently, the only available medication to raise HDL-C is nicotinic acid (niacin), taken in gram quantities. The data supporting niacin use for CAD prevention are much weaker than that for statins. Novel therapies aimed at raising HDL-C are the direct result of research in the complex mechanisms that modulate HDL in humans. These novel therapies will need to be tested not only for their ability to effectively and safely raise HDL-C, but for their ability to prevent CAD as well.",
keywords = "Dyslipidemia, HDL-cholesterol, Prevention",
author = "Zuhier Awan and Waili, {Khalid Al} and Khalid Alrasadi and Jacques Genest",
year = "2008",
month = "8",
doi = "10.1016/S0828-282X(08)71035-3",
language = "English",
volume = "24",
journal = "Canadian Journal of Cardiology",
issn = "0828-282X",
publisher = "Pulsus Group Inc.",
number = "SUPPL.C",

}

TY - JOUR

T1 - Treatment of low high-density lipoprotein cholesterol

AU - Awan, Zuhier

AU - Waili, Khalid Al

AU - Alrasadi, Khalid

AU - Genest, Jacques

PY - 2008/8

Y1 - 2008/8

N2 - The prevention of atherosclerotic vascular disease has changed considerably with the recognition that modifying cardiovascular risk factors (smoking, obesity, physical inactivity, elevated blood pressure, poor dietary habits, diabetes and elevated cholesterol levels) leads to a marked reduction in cardiovascular events. Reducing low-density lipoprotein cholesterol in high-risk subjects reduces cardiac events, cardiovascular mortality and total mortality. While epidemiological studies have consistently shown an inverse relationship between a low high-density lipoprotein cholesterol (HDL-C) level and the risk of coronary artery disease (CAD), there is a paucity of data showing unambiguously that raising HDL-C by pharmacological means reduces cardiac events. Lifestyle changes associated with an increase in HDL-C (smoking cessation, weight reduction, exercise, moderate alcohol intake) stand on their own merits with respect to cardiovascular benefits. Currently, the only available medication to raise HDL-C is nicotinic acid (niacin), taken in gram quantities. The data supporting niacin use for CAD prevention are much weaker than that for statins. Novel therapies aimed at raising HDL-C are the direct result of research in the complex mechanisms that modulate HDL in humans. These novel therapies will need to be tested not only for their ability to effectively and safely raise HDL-C, but for their ability to prevent CAD as well.

AB - The prevention of atherosclerotic vascular disease has changed considerably with the recognition that modifying cardiovascular risk factors (smoking, obesity, physical inactivity, elevated blood pressure, poor dietary habits, diabetes and elevated cholesterol levels) leads to a marked reduction in cardiovascular events. Reducing low-density lipoprotein cholesterol in high-risk subjects reduces cardiac events, cardiovascular mortality and total mortality. While epidemiological studies have consistently shown an inverse relationship between a low high-density lipoprotein cholesterol (HDL-C) level and the risk of coronary artery disease (CAD), there is a paucity of data showing unambiguously that raising HDL-C by pharmacological means reduces cardiac events. Lifestyle changes associated with an increase in HDL-C (smoking cessation, weight reduction, exercise, moderate alcohol intake) stand on their own merits with respect to cardiovascular benefits. Currently, the only available medication to raise HDL-C is nicotinic acid (niacin), taken in gram quantities. The data supporting niacin use for CAD prevention are much weaker than that for statins. Novel therapies aimed at raising HDL-C are the direct result of research in the complex mechanisms that modulate HDL in humans. These novel therapies will need to be tested not only for their ability to effectively and safely raise HDL-C, but for their ability to prevent CAD as well.

KW - Dyslipidemia

KW - HDL-cholesterol

KW - Prevention

UR - http://www.scopus.com/inward/record.url?scp=77949449210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949449210&partnerID=8YFLogxK

U2 - 10.1016/S0828-282X(08)71035-3

DO - 10.1016/S0828-282X(08)71035-3

M3 - Article

AN - SCOPUS:77949449210

VL - 24

JO - Canadian Journal of Cardiology

JF - Canadian Journal of Cardiology

SN - 0828-282X

IS - SUPPL.C

ER -